Second quarter (2021-10-01 - 2021-12-31)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2021-12-31 was 93 % (98 %).**
Six months (2021-07-01 - 2021-12-31)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2021-12-31 was 93 % (98 %).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of
** Solidity: Equity divided by total capital.
Highlights during Q2
- November -
ODI Pharma published its annual report for the fiscal year 2020/2021. -
December -
ODI Pharma held its Annual General Meeting in the office of the Company. A summary of the resolutions can be found on the Company's website (www.odipharma.com).
Comments by CEO
The second quarter of the fiscal year 2021/2022 has passed.
During the first quarter, we developed the launch of our exclusive CBD-infused skincare line kandol., an important step in the right direction for the brand kandol. This concluded with on
The first phase is designed to get the product in place for consumers in store and includes bulk sales. We have started working on the second phase of implementation for online, to create demand. We expect this to be developed over Q1-Q2 2022. This phase entails more complications than a non-CBD cosmetic brand, but we are confident of our success. The steps that we are completing now and are preparing for, represents an exciting growth of online sales but only after careful studies of partners and influencers. We believe that first half of 2022 is for study and are best spent to develop this network. Not spending now, but plan to build a significant compliment to the following years results. The reception of our products has been as good as we hoped but we still have a lot of work to do.
Tapping into what we see as great potential for our cosmetic products we continue to see it as a perfect complement for
ODI has with kandol. and its medical business always strived to be a financially conservative, step-by-step, progress and we have waited to increase the cost plan for our Polish medical business, nor have the founding partners taken any salary from ODI as promised. We see our growth as exciting and we are being careful to plan ahead.
Our primary focus of providing medicinal cannabis to Polish patients should not be overlooked. Project
I want to thank our investors for your trust in
Derek Simmross
CEO,
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
This information is the type of information that
https://news.cision.com/odi-pharma/r/odi-pharma-ab--publication-of-half-year-report-2021,c3514143
https://mb.cision.com/Main/19043/3514143/1540635.pdf
(c) 2022 Cision. All rights reserved., source